$12.29
5.77% yesterday
NYSE, May 20, 10:00 pm CET
ISIN
US29082K1051
Symbol
EMBC

Embecta Stock price

$12.29
+1.38 12.65% 1M
-1.32 9.70% 6M
-8.36 40.48% YTD
-1.64 11.77% 1Y
-15.46 55.71% 3Y
-34.71 73.85% 5Y
-34.71 73.85% 10Y
NYSE, Closing price Tue, May 20 2025
+0.67 5.77%
ISIN
US29082K1051
Symbol
EMBC
Sector

Key metrics

Market capitalization $718.26m
Enterprise Value $2.07b
P/E (TTM) P/E ratio 13.55
EV/FCF (TTM) EV/FCF 52.26
EV/Sales (TTM) EV/Sales 1.92
P/S ratio (TTM) P/S ratio 0.67
P/B ratio (TTM) P/B ratio negative
Dividend yield 4.88%
Last dividend (FY24) $0.60
Revenue growth (TTM) Revenue growth -4.68%
Revenue (TTM) Revenue $1.08b
EBIT (operating result TTM) EBIT $221.40m
Free Cash Flow (TTM) Free Cash Flow $39.70m
Cash position $212.30m
EPS (TTM) EPS $0.91
P/E forward 6.25
P/S forward 0.66
EV/Sales forward 1.91
Short interest 7.06%
Show more

Is Embecta a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Embecta Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Embecta forecast:

1x Buy
20%
3x Hold
60%
1x Sell
20%

Analyst Opinions

5 Analysts have issued a Embecta forecast:

Buy
20%
Hold
60%
Sell
20%

Financial data from Embecta

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,080 1,080
5% 5%
100%
- Direct Costs 404 404
3% 3%
37%
675 675
9% 9%
63%
- Selling and Administrative Expenses 343 343
24% 24%
32%
- Research and Development Expense 64 64
24% 24%
6%
268 268
30% 30%
25%
- Depreciation and Amortization 47 47
27% 27%
4%
EBIT (Operating Income) EBIT 221 221
31% 31%
21%
Net Profit 53 53
25% 25%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Embecta directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Embecta Stock News

Negative
Seeking Alpha
5 days ago
Embecta appears cheap at first glance, but its complete valuation picture includes heavy debt and significant earnings adjustments. The company's reliance on declining pen needle revenues and lack of innovation raise concerns about long-term growth and terminal value. The recent revenue decline is partly explained by temporary issues, but structural headwinds and competition from GLP-1 drugs al...
Neutral
Seeking Alpha
11 days ago
Embecta Corp. (NASDAQ:EMBC ) Q2 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Dev Kurdikar - President & CEO Jake Elguicze - CFO Pravesh Khandelwal - Vice VP, IR Conference Call Participants Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG Anthony Petrone - Mizuho Securities Michael Polark - Wolfe Research Operator Welcome, ladies and gentlemen, to Embecta Co...
Neutral
GlobeNewsWire
12 days ago
PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025.
More Embecta News

Company Profile

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.

Head office United States
CEO Devdatt Kurdikar
Employees 2,100
Founded 1924
Website www.embecta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today